Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus.


Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
07 03 2019
Historique:
received: 31 08 2018
revised: 26 11 2018
accepted: 25 01 2019
entrez: 9 3 2019
pubmed: 9 3 2019
medline: 7 1 2020
Statut: ppublish

Résumé

Respiratory syncytial virus (RSV) is a worldwide public health concern for which no vaccine is available. Elucidation of the prefusion structure of the RSV F glycoprotein and its identification as the main target of neutralizing antibodies have provided new opportunities for development of an effective vaccine. Here, we describe the structure-based design of a self-assembling protein nanoparticle presenting a prefusion-stabilized variant of the F glycoprotein trimer (DS-Cav1) in a repetitive array on the nanoparticle exterior. The two-component nature of the nanoparticle scaffold enabled the production of highly ordered, monodisperse immunogens that display DS-Cav1 at controllable density. In mice and nonhuman primates, the full-valency nanoparticle immunogen displaying 20 DS-Cav1 trimers induced neutralizing antibody responses ∼10-fold higher than trimeric DS-Cav1. These results motivate continued development of this promising nanoparticle RSV vaccine candidate and establish computationally designed two-component nanoparticles as a robust and customizable platform for structure-based vaccine design.

Identifiants

pubmed: 30849373
pii: S0092-8674(19)30109-6
doi: 10.1016/j.cell.2019.01.046
pmc: PMC6424820
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
CAV1 protein, human 0
Caveolin 1 0
F protein, human respiratory syncytial virus 0
Vaccines 0
Viral Fusion Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1420-1431.e17

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM099989
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM120553
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008268
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Références

Vaccine. 2013 Mar 15;31(12):1641-5
pubmed: 22884665
Vaccine. 2011 Aug 11;29(35):6059-67
pubmed: 21443960
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Comput Struct Biotechnol J. 2015 Nov 26;14:58-68
pubmed: 26862374
Immunity. 2018 Aug 21;49(2):301-311.e5
pubmed: 30076101
J Am Soc Mass Spectrom. 2013 Dec;24(12):1906-12
pubmed: 24018862
Nat Med. 2015 Sep;21(9):1065-70
pubmed: 26301691
Nature. 2016 Sep 14;537(7620):320-7
pubmed: 27629638
Vaccine. 2017 Jun 27;35(30):3749-3759
pubmed: 28579233
Elife. 2016 Nov 15;5:
pubmed: 27845625
J Virol. 2011 Aug;85(15):7788-96
pubmed: 21613394
Curr Opin Virol. 2016 Jun;18:44-9
pubmed: 27039982
J Am Soc Mass Spectrom. 2006 Dec;17(12):1700-3
pubmed: 16931036
Immunity. 2014 Oct 16;41(4):529-42
pubmed: 25367570
J Struct Biol. 2007 Jan;157(1):38-46
pubmed: 16859925
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3089-94
pubmed: 22323598
Nat Med. 2010 Jan;16(1):123-8
pubmed: 20023635
J Struct Biol. 2016 Jan;193(1):1-12
pubmed: 26592709
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9619-24
pubmed: 21586636
J Infect Dis. 2012 Jul 1;206(1):56-62
pubmed: 22529314
J Virol. 2016 May 12;90(11):5485-5498
pubmed: 27009962
Science. 2016 Jul 22;353(6297):389-94
pubmed: 27463675
J Struct Biol. 2009 May;166(2):205-13
pubmed: 19374019
Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1080-5
pubmed: 22247289
J Virol. 2016 Sep 29;90(20):9471-82
pubmed: 27512064
J Mol Biol. 2003 Oct 31;333(4):721-45
pubmed: 14568533
Vaccine. 2016 Jun 24;34(30):3535-41
pubmed: 27182820
Nature. 2014 Jun 5;510(7503):103-8
pubmed: 24870237
Nat Mater. 2013 Nov;12(11):978-90
pubmed: 24150416
PLoS One. 2012;7(11):e50852
pubmed: 23226404
Curr Top Microbiol Immunol. 2013;372:3-38
pubmed: 24362682
Vaccine. 2003 Jul 28;21(24):3479-82
pubmed: 12850364
Am J Dis Child. 1986 Jun;140(6):543-6
pubmed: 3706232
ACS Nano. 2017 Jan 24;11(1):54-68
pubmed: 28075558
J Infect Dis. 1998 Feb;177(2):463-6
pubmed: 9466538
Nat Microbiol. 2017 Jan 30;2:16272
pubmed: 28134915
Ultramicroscopy. 2013 Dec;135:24-35
pubmed: 23872039
Science. 2013 May 31;340(6136):1113-7
pubmed: 23618766
Nat Commun. 2018 May 15;9(1):1904
pubmed: 29765035
Arch Virol. 2016 Aug;161(8):2351-60
pubmed: 27216929
J Infect Dis. 2017 Jan 1;215(1):24-33
pubmed: 27694633
Nat Commun. 2017 Oct 20;8(1):1085
pubmed: 29057917
Nature. 2016 Dec 1;540(7631):150
pubmed: 27760110
Nat Commun. 2015 Sep 03;6:8143
pubmed: 26333350
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
Sci Immunol. 2016 Dec 16;1(6):
pubmed: 28111638
Nature. 2013 Sep 19;501(7467):439-43
pubmed: 23955151
Sci Rep. 2017 Apr 19;7:46621
pubmed: 28422178
Nucleic Acids Res. 2011 Nov;39(21):e143
pubmed: 21911364
Cell. 2015 Aug 27;162(5):1090-100
pubmed: 26279189
J Struct Biol. 2005 Jul;151(1):41-60
pubmed: 15890530
Science. 2015 Jul 10;349(6244):156-61
pubmed: 26089355
Nat Methods. 2017 Apr;14(4):331-332
pubmed: 28250466
Chem Rev. 2015 Oct 14;115(19):11109-46
pubmed: 26154342
Virology. 2015 May;479-480:498-507
pubmed: 25866377
Sci Transl Med. 2015 Oct 14;7(309):309ra162
pubmed: 26468324
Nature. 2013 Jul 4;499(7456):102-6
pubmed: 23698367
Nat Rev Immunol. 2010 Nov;10(11):787-96
pubmed: 20948547
Science. 2012 Jun 1;336(6085):1171-4
pubmed: 22654060
Nat Commun. 2016 Feb 24;7:10618
pubmed: 26907590
Retrovirology. 2015 Sep 26;12:82
pubmed: 26410741
Nat Struct Mol Biol. 2016 Sep;23(9):811-820
pubmed: 27478931
N Engl J Med. 2009 Feb 5;360(6):588-98
pubmed: 19196675
J Struct Biol. 2017 Apr;198(1):38-42
pubmed: 28254381
Protein Sci. 2018 Jan;27(1):14-25
pubmed: 28710774
Science. 2013 Nov 1;342(6158):592-8
pubmed: 24179220
Nat Commun. 2016 Jun 28;7:12041
pubmed: 27349934

Auteurs

Jessica Marcandalli (J)

Università della Svizzera italiana, Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.

Brooke Fiala (B)

Department of Biochemistry, University of Washington, Seattle, WA, USA; Institute for Protein Design, University of Washington, Seattle, WA, USA.

Sebastian Ols (S)

Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Michela Perotti (M)

Università della Svizzera italiana, Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland; Institute of Microbiology, ETH Zürich, Switzerland.

Willem de van der Schueren (W)

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Joost Snijder (J)

Department of Biochemistry, University of Washington, Seattle, WA, USA.

Edgar Hodge (E)

Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA.

Mark Benhaim (M)

Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA.

Rashmi Ravichandran (R)

Department of Biochemistry, University of Washington, Seattle, WA, USA; Institute for Protein Design, University of Washington, Seattle, WA, USA.

Lauren Carter (L)

Department of Biochemistry, University of Washington, Seattle, WA, USA; Institute for Protein Design, University of Washington, Seattle, WA, USA.

Will Sheffler (W)

Department of Biochemistry, University of Washington, Seattle, WA, USA; Institute for Protein Design, University of Washington, Seattle, WA, USA.

Livia Brunner (L)

Vaccine Formulation Laboratory, University of Lausanne, Epalinges, Switzerland.

Maria Lawrenz (M)

Vaccine Formulation Institute, Godalming, UK.

Patrice Dubois (P)

Vaccine Formulation Institute, Godalming, UK.

Antonio Lanzavecchia (A)

Università della Svizzera italiana, Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.

Federica Sallusto (F)

Università della Svizzera italiana, Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland; Institute of Microbiology, ETH Zürich, Switzerland.

Kelly K Lee (KK)

Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA; Biological Physics Structure and Design Program, University of Washington, Seattle, WA, USA.

David Veesler (D)

Department of Biochemistry, University of Washington, Seattle, WA, USA.

Colin E Correnti (CE)

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Lance J Stewart (LJ)

Department of Biochemistry, University of Washington, Seattle, WA, USA; Institute for Protein Design, University of Washington, Seattle, WA, USA.

David Baker (D)

Department of Biochemistry, University of Washington, Seattle, WA, USA; Institute for Protein Design, University of Washington, Seattle, WA, USA; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.

Karin Loré (K)

Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Laurent Perez (L)

Università della Svizzera italiana, Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland; European Virus Bioinformatics Center, Jena, Germany. Electronic address: laurent.perez@irb.usi.ch.

Neil P King (NP)

Department of Biochemistry, University of Washington, Seattle, WA, USA; Institute for Protein Design, University of Washington, Seattle, WA, USA. Electronic address: neilking@uw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH